WALDENSTRÖM MACROGLOBULINEMIA (WM)

Read 1295 times

1. Protocol Nο.: HOVON 124 WM/ECWM-R2
A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia

Study Locations in Greece:
Department of Clinical Therapeutics, «Alexandra» Hospital, Athens

2. ECMW-1:DRC with or without once-weekly subcutaneous bortezomib

Study Locations in Greece:
Department of Clinical Therapeutics, «Alexandra» Hospital, Athens

3. BEIGENE
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)

Study Locations in Greece:
Department of Clinical Therapeutics, «Alexandra» Hospital, Athens

4. HO-164 (in symptomatic  relapsed  WM )

Study Locations in Greece:
Department of Clinical Therapeutics, «Alexandra» Hospital, Athens